All News

EULAR19.abstract.jpg (keep)

Featured Abstracts from Industry at EULAR 2021

Jack Cush, MD

Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.

Read Article
RheumNow Podcast square

RheumNow Podcast – Heart, Lung & Liver (5.28.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
Vaccine2.jpg (keep)

Methotrexate Impairs COVID Vax Response

MedPage Today

One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.

Read Article
RNL, over, microphone

RheumNow Live 2021 Now Available for All

Jack Cush, MD

RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).

Read Article
#EULAR2021 OP0138 - Radiographic AxSpA in LDA, SPACING anti-TNF vs continue care. 83% were able to ⬆️ dosing interval at month 12, drug efficacy recovered in pts with relapsed disease. Worth trying in stable patient who wants to wean down meds. @RheumNow

Eric Dein ejdein1 ( View Tweet)

➡️ASTERA = PIII trial that showed superior efficacy of Netakimab (IL-17Ai) vs PBO in pts w/ active r-axSpA. Excluded pts prev tx w/ 2 or more TNFi ➡️OP0142 = sub-analysis showing Netak ⬇️ dz activity in AS pts irrespective of sacroillitis on MRI at b/l #EULAR2021 @Rheumnow https://t.co/faT3M0xQiR
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD ⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD ⭐️No overall increase in all CA: RTX, TOCI ⭐️Abatacept 1.21HR for all cancer, mainly NMSC ⭐️needs more data on JAKs, IL-17, IL-23 Abs#6916 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

From bedside to bench–unexpected results of clinical studies that changed our understanding of the disease #EULAR2021. “SpA” talk by Prof. Désirée van der Heijde. Inhibition of TNF, IL-17, IL-23, IL-6, IL-1, co-stimulation and B cell depletion in immunology perspective 👏 /TK https://t.co/JFr3VC8sXY
ARD & RMD Open ARD_BMJ ( View Tweet)
TNFi use associated with ⬇️ radiographic sacroilitis progression in patients with AxSpA ⭐️effect becomes evident between 2 and 4 years after treatment Abs#OP0137 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

SPACING trial OP0138 at #EULAR2021 ⭐️RCT by the French showing non-inferiority of spacing TNFi in r-axSpA pts w/ LDA (BASDAI<4 x 6mo) ⭐️ 88% in spacing group remained w/ LDA vs 91.5% in standard tx ⭐️ADA, CTZ, GOL, IFX spaced by 1w intervals. ETN by 3-4d & 1w. @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Dr Lukas presents data showing possibility of tapering a range of TNF in AxSpA patients in remission 162/184 (88.0%) LDA in progressive spacing group vs 173/189 (91.5%) in continued at 1 year.@RheumNow #EULAR2021 Abstr#0138

Richard Conway RichardPAConway ( View Tweet)

Abst#OP0137 at #EULAR2021: ➡️TNFi use for at least 1 year decreased radiographic sacroiliitis progression in early AxSpA in this ten year multicenter study of the German Spondyloarthritis Inception cohort (GESPIC) . ➡️This effect becomes evident 2-4 years after tx. @RheumNow https://t.co/GNnYqYmxhl
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

tofa/bari in RA H2H vs TNFi comparative efficacy studies highlighted (more head-to-head studies please!) @karolinskainst OP0122 #EULAR2021 @RheumNow (also Swedish national registry data showed tofa/bari comparable to non-TNFi bDMARDs, but no photos allowed!) https://t.co/CUWlK2O94h

David Liew drdavidliew ( View Tweet)
Dr Mekinian presents data showing TCZ and TNFi appear equally effective in TAK, complete response 66% vs 70% at 6 months @RheumNow #EULAR2021 Abstr#OP0068

Richard Conway RichardPAConway ( View Tweet)

To clot or NOT? Real world data usually show no ⬆️ VTE in RA with #Jaki compares to other advanced therapies. Diff from high CV risk pts in Oral Surveillance where Tofacitinib had higher VTE vs TNFi @AbbVie symposium @eular_org #EULAR2021 @RheumNow Hard to reconcile diff risk. https://t.co/AWY2zZPSIb
Janet Pope Janetbirdope ( View Tweet)

Do you think JAKi cause VTE? @eular_org @RheumNow #EULAR2021

Janet Pope Janetbirdope ( View Tweet)

News Feature: CV Risk Decreased with Certain DMARDs in Rheumatoid Arthritis A large prospective cohort study examined the comparative risks of CVD in patients with RA and found that, MTX, ABA & TNFi use were associated w/ a decreased risk of CV events. https://t.co/uQbtB76Hgy https://t.co/ftc5ys9C58

Links:

Dr. John Cush RheumNow ( View Tweet)
Listen to Dr. Jack Cush review the news and journal reports from the past week on RheumNow. Our latest podcast is available for download on SoundCloud, Apple and Android carplay. https://t.co/FvmmOBAjC1 https://t.co/rrZO6jOlKt

Links:

Dr. John Cush RheumNow ( View Tweet)
Listen to the latest RheumNow podcast--Myth Busters. Jack Cush discusses the latest rheum news on the site. Download wherever podcasts are available. https://t.co/q7FZTDo0BL https://t.co/fxGnyChzSO

Links:

Dr. John Cush RheumNow ( View Tweet)
BSRBR: Demyelinating Disease Following Anti-TNFα Therapy Analysis of patients receiving TNFi therapy in the BSRBR shows that the risk of demyelination is rare but is marginally increased by taking TNFi therapy. https://t.co/oHJXOa96Kn https://t.co/m2GpeEQxnP

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×